EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Multicenter basket trial for central nervous system tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma

Thomas J Kaley iD, Christian Grommes, Elizabeth Coffee, Robert J Young, Tara Morrison, Ahmad Daher iD, Lauren R Schaff, Yufei Deng, Subhiksha Nandakumar, Eli L Diamond iD, Lisa M DeAngelis, Katherine S Panageas und 10 weitere

Neuro-Oncology · 01.12.2025 · 27 (12) · 3189-3199

DOI: 10.1093/neuonc/noaf184 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Neuro-Oncology, online erschienen am 16.08.2025. Verfasst von Thomas J Kaley und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Weill Cornell Medical College, New York, New York, USA. Hauptthemen laut MEDLINE: Benzimidazoles, Aminopyridines, Meningioma, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Central nervous system (CNS) tumors are associated with considerable morbidity and high mortality. Cyclin-dependent kinases (CDKs) regulate cell division in cancer, and CDK4/6 inhibitors are used for the treatment of breast cancer, representing an attractive therapy for different tumor types.

Methods

Here, we report mature results of a multicenter basket trial exploring the CDK4/6 inhibitor abemaciclib in patients with recurrent CNS tumors, including patients with glioma, primary CNS lymphoma, meningioma, and ependymoma. We expanded our cohort of meningioma patients based on preliminary evidence for activity. Patients were treated with 200 mg oral abemaciclib twice daily for days 1–28, following FDA recommendations for breast cancer. Primary outcomes included radiographic response rates and progression-free survival (PFS) at 6 months post-treatment. We also evaluated overall survival (OS) and toxicity. Exploratory outcomes included next-generation sequencing of tumor biopsies.

Results

Most cohorts did not demonstrate activity with the exception of the cohort of patients with recurrent meningioma, including patients with grade 2 or 3 disease (19/22 meningioma patients). In that group, the median PFS was 15 months (95% CI: 6.5, not reached) and median OS was 32.9 months (95% CI: 10.7, not reached); the 6-month PFS was 68.2% (95% CI: 51.3%, 90.7%). All 22 patients were evaluable for radiographic response, showing stable disease in 16/22 (73%) and progressive disease in 6/22 patients (27%).

Conclusion

Our data suggest that abemaciclib improves PFS and OS in patients with advanced meningioma. The 6-month PFS with abemaciclib in this study (68.2%) exceeded RANO proposed benchmarks for activity (49%).

Trial registration

NCT03220646

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzimidazolesAminopyridinesMeningiomaNeoplasm Recurrence, LocalCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Meningeal NeoplasmsProtein Kinase InhibitorsCentral Nervous System NeoplasmsHumansFemaleMiddle AgedMaleAgedAdultSurvival RatePrognosisFollow-Up Studies

Stichwörter der Autor:innen

abemaciclibbrain tumorsclinical trialmeningioma

Substanzen

abemaciclibBenzimidazolesAminopyridinesCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Protein Kinase InhibitorsCDK4 protein, humanCDK6 protein, human

Autor:innen und Institutionen

  • Department of Neurology, Weill Cornell Medical College, New York, New York, USA.
  • Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Human Oncology and Pathogenesis Program, Sloan Kettering Institute, New York, NY, 10065, USA.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Lehigh Valley Hospital-Cedar Crest, Allentown, PA, USA.
  • Hartford HealthCare Cancer Institute, Plainville, CT, USA.

ORCID-Profile: Thomas J Kaley, Ahmad Daher, Eli L Diamond, Elena Pentsova

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Kaley, T. J., Grommes, C., Coffee, E., Young, R. J., Morrison, T., Daher, A., Schaff, L. R., Deng, Y., Nandakumar, S., Diamond, E. L., DeAngelis, L. M., Panageas, K. S., Gavrilovic, I., Lin, A., Pentsova, E., Stone, J., Santomasso, B. D., Piotrowski, A. F., Nair, S., …, & Mellinghoff, I. K. (2025). Multicenter basket trial for central nervous system tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma. Neuro-Oncology, 27(12), 3189-3199. https://doi.org/10.1093/neuonc/noaf184

Vancouver

Kaley TJ, Grommes C, Coffee E, Young RJ, Morrison T, Daher A, et al. Multicenter basket trial for central nervous system tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma. Neuro-Oncology. 2025;27(12):3189-3199. doi:10.1093/neuonc/noaf184

BibTeX
@article{Kaley2025,
  author = {Kaley, Thomas J and Grommes, Christian and Coffee, Elizabeth and Young, Robert J and Morrison, Tara and Daher, Ahmad and Schaff, Lauren R and Deng, Yufei and Nandakumar, Subhiksha and Diamond, Eli L and DeAngelis, Lisa M and Panageas, Katherine S and Gavrilovic, Igor and Lin, Andrew and Pentsova, Elena and Stone, Jacqueline and Santomasso, Bianca D and Piotrowski, Anna F and Nair, Suresh and Schultz, Nikolaus and Reiner, Anne S and Mellinghoff, Ingo K},
  title = {Multicenter basket trial for central nervous system tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma},
  journal = {Neuro-Oncology},
  year = {2025},
  volume = {27},
  number = {12},
  pages = {3189--3199},
  doi = {10.1093/neuonc/noaf184}
}
Kostenlos starten →